Royalty Pharma (RPRX) Price & Analysis

Compare

1,259 Followers

RPRX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$24.05 - $36.32

Previous CloseN/A

Volume726.99K

Average Volume (3M)5.48M

Market Cap

$20.19B

Enterprise Value$22.71B

Total Cash (Recent Filing)$1.82B

Total Debt (Recent Filing)$7.62B

Price to Earnings (P/E)14.7

Beta0.31

Next Earnings

Aug 06, 2025

EPS Estimate

1.04

Last Dividend Ex-Date

May 16, 2025

Dividend Yield2.45%

Share Statistics

EPS (TTM)0.41

Shares Outstanding421,370,670

10 Day Avg. Volume5,659,063

30 Day Avg. Volume5,480,405

Financial Highlights & Ratios

PEG Ratio-4.42

Price to Book (P/B)3.08

Price to Sales (P/S)0.00

P/FCF Ratio4.14

Enterprise Value/Market Cap1.12

Enterprise Value/Revenue2.51

Enterprise Value/Gross Profit10.07

Enterprise Value/Ebitda2.93

Forecast

1Y Price Target

$41.60

Price Target Upside15.85% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Royalty Pharma News

See All News >

Bulls Say, Bears Say

Bulls Say

Financial StrategyThe transaction sets Royalty Pharma on track to meet or exceed its 5-year capital deployment target, demonstrating confidence in their strategic direction.

Regulatory ApprovalsFDA has granted Breakthrough Therapy Designation to daraxonrasib for previously treated metastatic PDAC in patients with KRAS G12 mutations.

Royalty Financing DealThe announced royalty financing deal with Revolution Medicines allows Royalty Pharma to participate in the upside of the target asset daraxonrasib for oncology.

Bears Say

Management StrategyThe move to internalize the manager simplifies financial reporting and provides clear alignment between management and shareholders, but it might disrupt current operations.

Market CompetitionTremfya should fight Skyrizi to a draw in ulcerative colitis, and RPRX garners a tiered mid-single digit royalty on Tremfya through 2031-32.

Pipeline ChallengesThe company's growth profile is above the peer average, yet the lack of an internal pipeline could pose challenges to adapting to potential changes in the regulatory environment.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

1.86% Insiders

19.91% Mutual Funds

18.11% Other Institutional Investors

43.16% Public Companies and Individual Investors

Detailed Ownership Overview >

RPRX FAQ

What was Royalty Pharma PLC’s price range in the past 12 months?

Royalty Pharma PLC lowest stock price was $24.05 and its highest was $36.32 in the past 12 months.

What is Royalty Pharma PLC’s market cap?

Royalty Pharma PLC’s market cap is $20.19B.

When is Royalty Pharma PLC’s upcoming earnings report date?

Royalty Pharma PLC’s upcoming earnings report date is Aug 06, 2025 which is in 40 days.

How were Royalty Pharma PLC’s earnings last quarter?

Royalty Pharma PLC released its earnings results on May 08, 2025. The company reported $0.412 earnings per share for the quarter, missing the consensus estimate of $0.953 by -$0.541.

Is Royalty Pharma PLC overvalued?

According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Royalty Pharma PLC pay dividends?

Royalty Pharma PLC pays a Quarterly dividend of $0.22 which represents an annual dividend yield of 2.45%. See more information on Royalty Pharma PLC dividends here

What is Royalty Pharma PLC’s EPS estimate?

Royalty Pharma PLC’s EPS estimate is 1.04.

How many shares outstanding does Royalty Pharma PLC have?

Royalty Pharma PLC has 421,370,670 shares outstanding.

What happened to Royalty Pharma PLC’s price movement after its last earnings report?

Royalty Pharma PLC reported an EPS of $0.412 in its last earnings report, missing expectations of $0.953. Following the earnings report the stock price went up 1.076%.

Which hedge fund is a major shareholder of Royalty Pharma PLC?

Currently, no hedge funds are holding shares in RPRX

Royalty Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

16.57%

Trailing 12-Months

Asset Growth

9.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Royalty Pharma PLC

Royalty Pharma (RPRX) is a leading buyer of biopharmaceutical royalties and a significant player in the pharmaceutical and biotechnology sectors. The company acquires existing royalty interests in various drug products, providing capital to innovators and stakeholders in the healthcare industry. By focusing on a diversified portfolio of royalty interests, Royalty Pharma supports the development of groundbreaking therapies while generating substantial returns.

RPRX Company Deck

RPRX Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted Royalty Pharma's strong financial performance, dynamic capital allocation strategy, and significant portfolio expansions, alongside some concerns about policy uncertainties and ongoing disputes. The company remains optimistic about its future growth and market opportunities.Read More>

RPRX Revenue Breakdown

93.34% Income from financial royalty assets

6.62% Other royalty income

0.04% Revenue from intangible royalty assets

RPRX Stock 12 Month Forecast

Average Price Target

$41.60

▲(15.85%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","31":"$31","38":"$38","45":"$45","52":"$52"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$51.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,31,38,45,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.26,34.62461538461538,35.989230769230765,37.35384615384615,38.71846153846154,40.08307692307692,41.44769230769231,42.81230769230769,44.176923076923075,45.541538461538465,46.90615384615384,48.27076923076923,49.635384615384616,{"y":51,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.26,33.90153846153846,34.543076923076924,35.184615384615384,35.826153846153844,36.46769230769231,37.10923076923077,37.75076923076923,38.392307692307696,39.033846153846156,39.675384615384615,40.316923076923075,40.95846153846154,{"y":41.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.26,33.239999999999995,33.22,33.199999999999996,33.18,33.16,33.14,33.12,33.1,33.08,33.06,33.04,33.02,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.62,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.44,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.67,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.41,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.78,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.52,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.16,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.42,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.96,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.26,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >